Company / Operating Cash Flow
Edgewise Therapeutics, Inc. Operating Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$143.8M
FY2025
5-year range
-$143.8M / -$33.5M
FY2021-FY2025
Trend
-31.9%
vs FY2024
Sector context
#147 of 216
Health Care
What the data says
At -$144M, Edgewise Therapeutics, Inc.'s operating cash flow ranks #147 of 216 in the Health Care sector. Operating Cash Flow has declined for 5 consecutive years, from -$15M in FY2020 to -$144M in FY2025.
Based on SEC 10-K filings.
-$144M in FY2025.
Declined from -$92M to -$144M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#147 of 216 in Health CareTop 68% of 216This company -$143.8M Sector average $659.0M
▼
-121.8% below sector average
Key checks
Key Insights
- Edgewise Therapeutics, Inc.'s operating cash flow has declined for 5 consecutive years.
- In FY2025, operating cash flow decreased 31.9% year-over-year.
- Ranks #147 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$143.8M | -31.9% |
| FY2024 | -$109.0M | -18.6% |
| FY2023 | -$91.9M | -74.7% |
| FY2022 | -$52.6M | -57.1% |
| FY2021 | -$33.5M | -129.0% |
| FY2020 | -$14.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026